Epitopea has successfully closed a USD $31 million pre-Series A financing round to support the development and clinical entry of its innovative RNA-based cancer immunotherapies.
Information on the Target
Epitopea is a transatlantic company focused on developing innovative cancer immunotherapeutics, specifically RNA-based therapies designed to be off-the-shelf solutions. The company aims to address the significant unmet medical need presented by hard-to-treat solid tumors, where current treatment options often yield poor survival rates. The company's proprietary CryptoMap™ platform is crucial for identifying a novel class of tumor-specific antigens (Cryptigen™ TSAs), which are shared broadly among patients with the same tumor type.
Founded in 2021, Epitopea has quickly gained traction in the biotech sector, raising over USD $45 million to date. The company operates out of Cambridge, UK, and Montreal, Canada, promoting cross-border collaboration to enhance its research and development capabilities.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in Canada
The Canadian biotechnology landscape is rapidly evolving, characterized by a robust ecosystem that supports innovation in life sciences. With significant investments from both public and private sectors, the Canadian biotech industry is i
Similar Deals
Conexus Venture Capital → Alto Technologies Inc.
2025
Investissement Québec, adMare BioInnovations, Jonathan Milner, Advent Life Sciences, CTI Life Sciences, Cambridge Innovation Capital, Fonds de Solidarité FTQ, Harrington Discovery Institute, IRICoR, Novateur Ventures
invested in
Epitopea
in 2024
in a Pre-Seed Stage deal
Disclosed details
Transaction Size: $31M